Table 1 Baseline preoperative characteristics and comorbidities
| Â | Study population | heparin (H) | argatroban (A) | H vs. A: p-value | switched (S) | H vs. S: p-value |
|---|---|---|---|---|---|---|
Number | 215 | 143 | 43 | 29 | ||
| Â | mean (SD) o. % (n) | mean (SD) o. % (n) | mean (SD) o. % (n) | mean (SD) o. % (n) | ||
Male | 61% (131) | 64% (91) | 49% (21) | n.s. | 66% (19) | n.s. |
Age (years) | 69,8 ± 10,7 | 68,6 ± 11,6 | 71,5 ± 8,4 | n.s. | 74,4 ± 7,2 | 0,01 |
BMI [kg/m2] | 28 ± 4,8 | 28 ± 4 | 28 ± 5 | n.s. | 29 ± 7 | n.s. |
SAPS II Score | 28,5 ± 15,3 | 26 ± 13 | 39 ± 14 | < 0,001 | 27 ± 20 | n.s. |
EuroSCORE 2 | 9 ± 9,1 | 8,6 ± 9,1 | 11,1 ± 10,1 | n.s. | 8,0 ± 7,1 | n.s. |
Diabetes([%] | 29% (63) | 24% (35) | 35% (15) | n.s. | 45% (13) | 0,04 |
Hb [g/dL] | 13,2 ± 2,0 | 13,3 ± 2,0 | 12,5 ± 1,9 | 0,02 | 13,8 ± 1,6 | n.s. |
End stage renal desease | 3% (6) | 3% (5) | 2% (1) | n.s. | 0% (0) | n.s. |
Hepatic dysfunction | 5% (10) | 4% (6) | 2% (1) | n.s. | 10% (3) | n.s. |
Chronic pulmonary disease | 17% (36) | 15% (21) | 19% (8) | n.s. | 24% (7) | n.s. |